Company news
Editas Medicine, Inc. news in 2019
Editas Medicine, Inc.'s news releases, calls and decks from 2019, newest first.
Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia
December 8, 2019
Editas Medicine Announces Third Quarter 2019 Results and Update
November 11, 2019
Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases
November 11, 2019
Editas Medicine to Host Conference Call Discussing Third Quarter 2019 Results and Corporate Update
November 4, 2019
Editas Medicine Appoints Judith R. Abrams, M.D., as Chief Medical Officer
October 27, 2019
Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases
October 14, 2019
Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines
October 6, 2019
Decks in 2019
- Technical Presentation (October 2019)
Technical · 21 slides · October 2019
- Investor Presentation (May 2019)
Investor deck · 30 slides · May 9, 2019